ArticleInvestigative ophthalmology & visual science2025
Metabolic Reprogramming in Retinoblastoma Patients: Treatment Naïve Active Retinoblastoma Versus Regressed Tumors Post-Treatment.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to explore and compare the serum metabolic alterations in treatment-naïve active retinoblastoma (RB) and regressed RB post-treatment. Methods: Analysis of serum metabolites in six patients with RB before, during, and after completion of treatment and their comparison with six age-matched controls. Serum metabolomics was performed by using 1H nuclear magnetic resonance (NMR) spectroscopy. Results: Serum metabolomics yielded 70 metabolites, including amino acids, carbohydrates, and organic acids, in patients with RB and healthy controls. Distinct serum metabolite clusters were noted in the PLSDA model for controls, patients with treatment-naïve active RB (AR), and patients with regressed tumors post-treatment (RT). Statistical analysis of metabolic profiles revealed a change in serum metabolite profiles in patients with RT compared with patients with AR. Several metabolites that were up- or downregulated in patients with RT were the intermediates of glycolysis, the tricarboxylic acid (TCA) cycle, and the membrane synthesis pathway. It has been observed that a few metabolites, such as GABA, aspartate, biotin, methionine, arginine, creatine, and lactate, which were upregulated in patients with AR with respect to controls, were suppressed in patients with RT. Additionally, monitoring the concentration of specific metabolites in patients with RB after each treatment cycle revealed that all treated patients with RB and with RT have a similar pattern of increase/decrease of metabolites with respect to their concentrations compared with their AT counterparts. However, they have followed distinct trajectories based on the status of the tumor during treatment cycle. Conclusions: The serum metabolic profile changes based on tumor status (active versus regressed). Serum metabolites may serve as a prognostic biomarker suggestive of tumor activity and response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.